Metronomic Oral Cyclophosphamide in Patients with Advanced Solid Tumors

Publisher： Karger

E-ISSN： 2296-5262|35|1-2|35-38

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.1-2, 2012-01, pp. : 35-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 98-104

Karger

Access to resources Recommend Favorite

Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Single-Center Pilot Study

By  

Oncology Research and Treatment, Vol. 29, Iss. 7, 2006-07 ,pp. : 308-313

Karger

Access to resources Recommend Favorite

Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 81, Iss. 2, 2011-09 ,pp. : 65-72

Karger

Access to resources Recommend Favorite

A Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors

By  

Oncology, Vol. 71, Iss. 5-6, 2007-09 ,pp. : 347-353

Karger

Access to resources Recommend Favorite

Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 253-259

Karger

Access to resources Recommend Favorite